An early access to medicines scheme in the UK could benefit medical research, bioscience companies and ultimately patient outcomes, according to the BioIndustry Association.
The BIA’s comments were in a response to a consultation launched by the Medicines and Healthcare products Regulatory Agency, which closed on 5 October.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.